

■■■■■

PATIENT INFORMATION LEAFLET
GAVISCON ADVANCE MINT CHEWABLE TABLETS

Sodium alginate
Potassium bicarbonate

Please read this leaflet carefully before you take this medicine. If you are not sure about anything ask your pharmacist or doctor.

What are Gaviscon Advance Mint Chewable Tablets?

Gaviscon Advance Mint Chewable Tablets belong to a group of medicines called 'reflux suppressants', which form a protective layer on top of the stomach contents to prevent stomach acid escaping from the stomach where it works into the food pipe causing pain and discomfort.

What are Gaviscon Advance Mint Chewable Tablets used for?

Gaviscon Advance Mint Chewable Tablets are used for the treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion, which may occur, for example, following meals or during pregnancy, and in patients with symptoms related to oesophagitis.

It can also be used to relieve the symptoms of conditions such as hiatus hernia (protrusion of muscle through a muscle wall), symptoms of hoarseness and other voice disorders, sore throat and cough associated with reflux. It can be taken to control heartburn symptoms which may occur while taking, or following withdrawal of medication to reduce stomach acid such as Proton Pump Inhibitors (PPI's) or H2 Antagonists.

Before using Gaviscon Advance Mint Chewable Tablets:

Do not take this product if:

- You know you are allergic to any of the ingredients as very rarely difficulty in breathing and skin rashes have occurred (see further information for a full list of ingredients).

Take special care before treatment with Gaviscon Advance Mint Chewable Tablets:

This medicine contains calcium (1.0 mmol per tablet dose).

This medicine contains 1.01 mmol (39.43 mg) potassium per tablet.

To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.

This medicine contains 53.22 mg sodium (main component of cooking/table salt) in each tablet. This is equivalent to 2.7 % of the recommended maximum daily dietary intake of sodium for an adult).

- If you have been advised to follow a diet restricted in any of these salts please consult your doctor before taking this product.
- The maximum recommended daily dose of this medicinal product contains 425.76 mg sodium (found in table salt). This is equivalent

to 21.28 % of the adult recommended maximum daily dietary intake for sodium.

- Talk to your pharmacist or doctor if you need Gaviscon Advance Mint Chewable Tablets on a daily basis for a prolonged period of time, especially if you have been advised to have a low salt diet.

This product contains 4.5 mg of aspartame (E951) in each tablet. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription. Wait at least 2 hours between taking this medicine and other medicines such as tetracyclines, fluoroquinolones (types of antibiotics), iron salts, thyroid hormones, chloroquine (a medication used to prevent malaria), bisphosphonates (a medication used to treat osteoporosis) and estramustine (a medication to treat prostate cancer).

Pregnancy and breast-feeding:

You can take this product if you are pregnant or breast-feeding. As with all medicines, the treatment duration should be limited as much as possible.

How to take Gaviscon Advance Mint Chewable Tablets:

For oral administration. Chew thoroughly before swallowing.

Adults and children over 12 years: When symptoms occur take one to two tablets after meals and at bedtime.

Children under 12 years: Should only be taken on medical advice.

If you forget a dose it is not necessary to double the dose next time, just carry on taking as before.

If you take too much of this product you may feel bloated and experience some abdominal discomfort. It is unlikely to cause you any harm, but please consult your doctor or pharmacist.

After taking Gaviscon Advance Mint Chewable Tablets:

If symptoms persist after 7 days consult your doctor.

Possible side effects

Very rarely (less than 1 in 10,000 patients treated), there is chance of an allergic reaction to the ingredients. Symptoms of this may include skin rash, difficulty in breathing, dizziness, or swelling of the face, lips, tongue or throat. Uncommonly reported side-effects are diarrhoea, nausea and vomiting (less than 1 in 100 people). If you experience these or any other side-effects stop taking the product and consult your doctor or pharmacist.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:

"<http://www.mhra.gov.uk/yellowcard>" or search for MHRA Yellow Card

0000000

in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

Storing your medicine:

Do not use after the expiry date (EXP month/year) shown on the pack.

KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.

Do not store above 30°C. Store in the original package.

Further information

Gaviscon Advance Mint Chewable Tablets are off-white to cream, circular, flat with bevelled edges tablets with the odour and flavour of peppermint. Each tablet contains sodium alginate 500 mg and potassium bicarbonate 100 mg as the active ingredients.

The other ingredients are sodium, mannitol (E421), calcium carbonate, macrogol 20,000, magnesium stearate, aspartame (E951), mint flavour, acesulfame potassium, copovidone.

These tablets do not contain sugar or gluten.

Gaviscon Advance Mint Chewable Tablets are available in pack sizes of 12's, 24's and 60's. Not all pack sizes are marketed

Manufacturer and PL Holder:

Reckitt Benckiser Healthcare (UK) Limited, Dansom Lahe, Hull, HU8 7DS.

Gaviscon is a trade mark of the Reckitt group.

Text revised: June 2024